FIELD: pharmaceutics.
SUBSTANCE: present invention relates to pharmaceutical compositions and methods for the prevention of a respiratory infection caused by a human rhinovirus (HRV) and a human influenza virus. In particular, a pharmaceutical composition is proposed for the prevention of an infection caused by rhinovirus in a human, containing: (i) soluble ICAM-1, (ii) lysozyme, (iii) lactoferrin, as well as a pharmaceutically acceptable carrier.
EFFECT: invention allows for enhancing the capability of membranes of the respiratory tract of filtering pathogens present in the air and protecting a subject from a respiratory infection occurred in the result of inhaling such pathogens.
20 cl, 42 dwg, 6 tbl, 5 ex
